-
3-propyl-2,3,6,9-tetrahydro-1H-purine-2,6-dione
-
ChemBase ID:
703
-
Molecular Formular:
C8H10N4O2
-
Molecular Mass:
194.1906
-
Monoisotopic Mass:
194.08037558
-
SMILES and InChIs
SMILES:
O=c1n(CCC)c2nc[nH]c2c(=O)[nH]1
Canonical SMILES:
CCCn1c(=O)[nH]c(=O)c2c1nc[nH]2
InChI:
InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14)
InChIKey:
SIQPXVQCUCHWDI-UHFFFAOYSA-N
-
Cite this record
CBID:703 http://www.chembase.cn/molecule-703.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
3-propyl-2,3,6,9-tetrahydro-1H-purine-2,6-dione
|
3-propyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione
|
|
|
IUPAC Traditional name
|
3-propyl-1,9-dihydropurine-2,6-dione
|
enprofylline
|
3-propylxanthine
|
|
|
Brand Name
|
|
Synonyms
|
3-Propylxanthine
|
Enprofylline
|
3-n-PROPYLXANTHINE
|
3-n-Propylxanthine
|
3-Propylxanthine
|
Enprofilina [INN-Spanish]
|
Enprofyllinum [INN-Latin]
|
Enprofylline
|
|
|
CAS Number
|
|
EC Number
|
|
MDL Number
|
|
Beilstein Number
|
|
PubChem SID
|
|
PubChem CID
|
|
CHEBI ID
|
|
CHEMBL
|
|
Chemspider ID
|
|
DrugBank ID
|
|
Unique Ingredient Identifier
|
|
Wikipedia Title
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
7.832659
|
H Acceptors
|
3
|
H Donor
|
2
|
LogD (pH = 5.5)
|
-0.11547689
|
LogD (pH = 7.4)
|
-0.23420627
|
Log P
|
-0.11366738
|
Molar Refractivity
|
49.3104 cm3
|
Polarizability
|
17.9433 Å3
|
Polar Surface Area
|
78.09 Å2
|
Rotatable Bonds
|
2
|
Lipinski's Rule of Five
|
true
|
Log P
|
0.35
|
LOG S
|
-1.53
|
Solubility (Water)
|
5.68e+00 g/l
|
DETAILS
DETAILS
MP Biomedicals
DrugBank
Wikipedia
Sigma Aldrich
DrugBank -
DB00824
|
Item |
Information |
Drug Groups
|
approved |
Description
|
Enprofylline is a derivative of theophylline which shares bronchodilator properties. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. Long-term enprofylline administration may be associated with elevation in liver enzyme levels and unpredictable blood levels. |
Indication |
Used in the management of symptoms of asthma. Also used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. |
Pharmacology |
Enprofylline is a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine. It antagonizes erythrocyte phosphodiesterase, increasing cAMP activity. |
Affected Organisms |
• |
Humans and other mammals |
|
Absorption |
Rapidly absorbed from the digestive tract |
Half Life |
1.9 hours |
Protein Binding |
49% |
|
Sigma Aldrich -
P5679
|
Biochem/physiol Actions Weak competitive antagonist at both A1 and A2 adenosine receptors. |
PATENTS
PATENTS
PubChem Patent
Google Patent